Cellosaurus cell line MDA-IBC-3 (CVCL_HC47)

PubMed=20808935; DOI=10.1371/journal.pone.0012180
Klopp A.H., Lacerda L., Gupta A., Debeb B.G., Solley T., Li L., Spaeth E., Xu W., Zhang X.-M., Lewis M.T., Reuben J.M., Krishnamurthy S., Ferrari M., Gaspar R., Buchholz T.A., Cristofanilli M., Marini F., Andreeff M., Woodward W.A.
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.
PLoS ONE 5:E12180-E12180(2010)

DOI=10.4172/2161-0681.1000119
Robertson F.M., Chu K., Fernandez S.V., Mu Z.-M., Zhang X.-J., Liu H., Boley K.M., Alpaugh R.K., Ye Z.-M., Wright M.C., Luo A.Z., Oraes R., Wu H., Zook M., Barsky S.H., Krishnamurthy S., Cristofanilli M.
Genomic profiling of pre-clinical models of inflammatory breast cancer identifies a signature of epithelial plasticity and suppression of TGFbeta signaling.
J. Clin. Exp. Pathol. 2:119.1-119.11(2012)

PubMed=23784380; DOI=10.1007/s10549-013-2600-4
Fernandez S.V., Robertson F.M., Pei J.-M., Aburto-Chumpitaz L., Mu Z.-M., Chu K., Alpaugh R.K., Huang Y., Cao Y., Ye Z.-M., Cai K.Q., Boley K.M., Klein-Szanto A.J.P., Devarajan K., Addya S., Cristofanilli M.
Inflammatory breast cancer (IBC): clues for targeted therapies.
Breast Cancer Res. Treat. 140:23-33(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=35042871; DOI=10.1038/s41523-021-00379-6
Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V., Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L., Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
NPJ Breast Cancer 8:12.1-12.12(2022)